To estimate the 2-year local control rate for adjuvant hypofractionated RT to the primary tumor bed.~To estimate the 2-year nodal control rate for adjuvant hypofractionated RT to the primary draining nodal basin.~Secondary Objectives~To determine MCC disease outcomes including:time to non-nodal locoregional recurrence, time to nodal recurrence, time to distant mestasis, disease-free-survival and disease-specific survival for patients receiving hypofractionated adjuvant RT.~To assess acute and late RT associated toxicity within or neighboring the radiated field.
This study seeks to determine the safety and efficacy of shortening the primary and nodal adjuvant radiation therapy course from 2 Gy x 25 fractions to 3.6 Gy x 10 fractions in merkel cell carcinoma patients who may or may not be receiving immunotherapy.